This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Gerresheimer Begins Financial Year 2013 With Strong Revenue Growth

For financial year 2013, Gerresheimer continues to anticipate revenue growth of 5% to 6% at constant exchange rates, even though this forecast seems slightly more conservative now against the background of the strong revenue growth in the first quarter of 2013. The company expects to generate an adjusted EBITDA margin of approximately 19.4%. Due to the healthy growth prospects, capital expenditure in financial year 2013 will be on a par with the past financial year, meaning some 9% to 10% of the revenue at constant exchange rates.

"Of key importance is the expansion of our production capacity for glass and plastic medical application systems at our Bünde and Pfreimd plants in Germany and our Horsovsky Tyn plant in the Czech Republic. The second major growth factor consists in boosting local production for primary glass and plastic pharma packaging in dynamic emerging markets," explained Uwe Röhrhoff.

The Gerresheimer Group has elected early application of IAS 19 Employee Benefits (revised 2011) with effect from December 1, 2012. Prior-year figures in tables in this press release and the Interim Report are therefore pro forma. Detailed information on the effects of the restatements is provided in the Notes section of the Interim Report.

Cross reference: The full press release including tables is available at:

The online annual report is available at:


Jens Kürten Director Corporate Communication & Marketing Telphone +49-211-6181-250 Fax +49-211-6181-241 E-Mail Internet

SOURCE Gerresheimer AG

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,050.75 +138.46 0.82%
S&P 500 2,013.43 +15.91 0.80%
NASDAQ 4,810.7880 +19.6360 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs